Biologics for extraintestinal manifestations of IBD

Current Drug Targets

Volumn 15, Issue 11, 2014, Pages 1064-1073

  Vavricka, Stephan R ^a,b   Scharl, Michael ^a   Gubler, Martin ^a   Rogler, Gerhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b TRIEMLI HOSPITAL   (Switzerland)

Author keywords

Arthritis; Extraintestinal manifestations; Inflammatory bowel disease; Uveitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; SALICYLIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; APHTHOUS STOMATITIS; ARTHRITIS; ARTHROPATHY; ARTICLE; AXIAL ARTHROPATHY; CROHN DISEASE; EPISCLERITIS; ERYTHEMA NODOSUM; EXTRAINTESTINAL MANIFESTATION; EYE DISEASE; HEPATOBILIARY DISEASE; HUMAN; INFLAMMATORY BOWEL DISEASE; MULTICENTER STUDY (TOPIC); MUSCULOSKELETAL DISEASE; PERIPHERAL ARTHRITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL DISEASE BY ANATOMICAL STRUCTURE; PRIMARY SCLEROSING CHOLANGITIS; PYODERMA GANGRENOSUM; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATIC DISEASE; SCLERITIS; SKIN MANIFESTATION; SPONDYLOARTHROPATHY; TREATMENT OUTCOME; ULCERATIVE COLITIS; UVEITIS;

EID: 84925864300     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666140908125453     Document Type: Article

References (96)

1. Danese S, Semeraro S, Papa A, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 2005; 11: 7227-36.
2. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001; 96: 1116-22.
3. Ricart E, Panaccione R, Loftus EV, Jr., et al. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 2004; 10: 207-14.
4. Mendoza JL, Lana R, Taxonera C, et al. [Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn's disease and ulcerative colitis]. Med Clin 2005; 125: 297-300.
5. Rankin GB, Watts HD, Melnyk CS, Kelley ML, Jr. National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology 1979; 77: 914-20.
6. Su CG, Judge TA, Lichtenstein GR. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am 2002; 31: 307-27.
7. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine 1976; 55: 401-12.
8. Farmer RG, Hawk WA, Turnbull RB, Jr. Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology 1975; 68: 627-35.
9. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 1996; 23: 29-34.
10. Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 2011; 106: 110-9.
11. Monsen U, Sorstad J, Hellers G, Johansson C. Extracolonic diagnoses in ulcerative colitis: an epidemiological study. Am J Gastroenterol 1990; 85: 711-6.
12. Das KM. Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Dig Dis Sci 1999; 44: 1-13.
13. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006; 12: 4819-31.
14. Trikudanathan G, Venkatesh PG, Navaneethan U. Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease. Drugs 2012; 72: 2333-49.
15. Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 1598-619.
16. Orchard TR, Chua CN, Ahmad T, et al. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 2002; 123: 714-8.
17. Caspersen S, Elkjaer M, Riis L, et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 2008; 6: 1212-7; quiz 1176.
18. Generini S, Giacomelli R, Fedi R, et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 2004; 63: 1664-9.
19. Kaufman I, Caspi D, Yeshurun D, et al. The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatology international 2005; 25: 406-10.
20. Kugathasan S, Miranda A, Nocton J, et al. Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr 2003; 37: 150-4.
21. Rispo A, Scarpa R, Di Girolamo E, et al. Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease. Scandinavian journal of rheumatology 2005; 34: 387-91.
22. Barreiro-de-Acosta M, Lorenzo A, Dominguez-Munoz JE. Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease. Rev Esp Enferm Dig 2012; 104: 468-72.
23. Lofberg R, Louis EV, Reinisch W, et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE. Inflamm Bowel Dis 2012; 18: 1-9.
24. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005; 129: 827-36.
25. Smale S, Natt RS, Orchard TR, et al. Inflammatory bowel disease and spondylarthropathy. Arthritis Rheum 2001; 44: 2728-36.
26. Gravallese EM, Kantrowitz FG. Arthritic manifestations of inflammatory bowel disease. Am J Gastroenterol 1988; 83: 703-9.
27. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998; 42: 387-91.
28. Bourikas LA, Papadakis KA. Musculoskeletal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 1915-24.
29. Brakenhoff LK, van der Heijde DM, Hommes DW. IBD and arthropathies: a practical approach to its diagnosis and management. Gut 2011; 60: 1426-35.
30. Ellman MH, Hanauer S, Sitrin M, Cohen R. Crohn's disease arthritis treated with infliximab: an open trial in four patients. J Clin Rheumatol 2001; 7: 67-71.
31. Herfarth H, Obermeier F, Andus T, et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease. Am J Gastroenterol 2002; 97: 2688-90.
32. Schwartz DA, Lofberg R, Pollack P, et al. Adalinumab-treated patients with moderate to severe Crohn's disease experienced reductions in extraintestinal manifistations data from CHARM. Am J Gastroenterol 2009; 104: S456 (abstract 1244).
33. Fornaciari G, Salvarani C, Beltrami M, et al. Muscoloskeletal manifestations in inflammatory bowel disease. Can J Gastroenterol 2001; 15: 399-403.
34. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-93.
35. Van den Bosch F, Kruithof E, De Vos M, et al. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000; 356: 1821-2.
36. Van Den Bosch F, Kruithof E, Baeten D, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002; 46: 755-65.
37. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 2136-46.
38. Freeman HJ. Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn's disease. Can J Gastroenterol 2005; 19: 603-6.
39. Ortego-Centeno N, Callejas-Rubio JL, Sanchez-Cano D, Caballero-Morales T. Refractory chronic erythema nodosum successfully treated with adalimumab. J Eur Acad Dermatol Venereol: JEADV 2007; 21: 408-10.
40. Quin A, Kane S, Ulitsky O. A case of fistulizing Crohn's disease and erythema nodosum managed with adalimumab. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 278-81.
41. Clayton TH, Walker BP, Stables GI. Treatment of chronic erythema nodosum with infliximab. Clin Expe Dermatol 2006; 31: 823-24.
42. Nguyen GC, Torres EA, Regueiro M, et al. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol 2006; 101: 1012-23.
43. Orchard T. Extraintestinal complications of inflammatory bowel disease. Curr Gastroenterol Rep 2003; 5: 512-7.
44. Chow RK, Ho VC. Treatment of pyoderma gangrenosum. J Am Acad Dermatol 1996; 34: 1047-60.
45. Arnott ID, McDonald D, Williams A, Ghosh S. Clinical use of Infliximab in Crohn's disease: the Edinburgh experience. Aliment Pharmacol Ther 2001; 15: 1639-46.
46. Batres LA, Mamula P, Baldassano RN. Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease. J Pediatr Gastroenterol Nutr 2002; 34: 558-60.
47. Brooklyn TN, Dunnill MG, Shetty, A et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006; 55: 505-9.
48. Ferkolj I, Hocevar A, Golouh R, Dolenc Voljc M. Infliximab for treatment of resistant pyoderma gangrenosum associated with Crohn's disease. Acta dermatovenerologica Alpina, Pannonica, et Adriatica 2006; 15: 173-7.
49. Grange F, Djilali-Bouzina F, Weiss AM, et al. Corticosteroidresistant pyoderma gangrenosum associated with Crohn's disease: rapid cure with infliximab. Dermatology 2002; 205: 278-80.
50. Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 2000; 284: 1546-8.
51. Juillerat P, Christen-Zach S, Troillet FX, et al. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review. Dermatology 2007; 215: 245-51.
52. Kiran RP, O'Brien-Ermlich B, Achkar JP, et al. Management of peristomal pyoderma gangrenosum. Dis Colon Rectum 2005; 48: 1397-403.
53. Kouklakis G, Moschos J, Leontiadis GI, et al. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report. Rom J Gastroenterol 2005; 14: 401-3.
54. Ljung T, Staun M, Grove O, et al. Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol 2002; 37: 1108-10.
55. Fonder MA, Cummins DL, Ehst BD, et al. Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds 2006; 5: e8.
56. Martin D, Handler T, McDermott J. Leucocytoclastic vasculitis in severe ulcerative colitis. Military medicine 2011; 176: 581-3.
57. Regueiro M, Valentine J, Plevy S, et al. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003; 98: 1821-6.
58. López San Román A, Bermejo F, Aldanondo I, Carrera E, Boixeda D, Muñoz Zato E. Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab. Rev Esp Enferm Dig 2004; 96(6): 420-2; 422-4.
59. Sapienza MS, Cohen S, Dimarino AJ. Treatment of pyoderma gangrenosum with infliximab in Crohn's disease. Dig Dis Sci 2004; 49: 1454-7.
60. Sheldon DG, Sawchuk LL, Kozarek RA, Thirlby RC. Twenty cases of peristomal pyoderma gangrenosum: diagnostic implications and management. Arch Surg 2000; 135: 564-568; discussion 568-569.
61. Singh M, Andrew SM, Lear JT. Infliximab as a treatment for recalcitrant pyoderma gangrenosum. Clin Exp Dermatol 2004; 29: 196-7.
62. Tan MH, Gordon M, Lebwohl O, et al. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol 2001; 137: 930-3.
63. Triantafillidis JK, Cheracakis P, Sklavaina M, Apostolopoulou K. Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum. Scand J Gastroenterol 2002; 37: 863-5.
64. Zaccagna A, Bertone A, Puiatti P, et al. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease. Eur J Dermatol 2003; 13(3): 258-60.
65. Alkhouri N, Hupertz V, Mahajan L. Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease. Inflamm Bowel Dis 2009; 15: 803-6.
66. Pomerantz RG, Husni ME, Mody E, Qureshi AA. Adalimumab for treatment of pyoderma gangrenosum. Br J Dermatol 2007; 157: 1274-5.
67. Zold E, Nagy A, Devenyi K, et al. Successful use of adalimumab for treating fistulizing Crohn's disease with pyoderma gangrenosum: Two birds with one stone. World J Gastroenterol 2009; 15: 2293-5.
68. Mimouni D, Anhalt GJ, Kouba DJ, Nousari HC. Infliximab for peristomal pyoderma gangrenosum. Br J Dermatol 2003; 148: 813-6.
69. Brunasso AM, Laimer M, Massone C. Paradoxical reactions to targeted biological treatments: A way to treat and trigger? Acta Derm Venereol 2010; 90: 183-5.
70. Vandevyvere K, Luyten FP, Verschueren P, et al. Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis. Clin Rheumatol 2007; 26(12): 2205-6.
71. Petrelli EA, McKinley M, Troncale FJ. Ocular manifestations of inflammatory bowel disease. Ann Ophthalmol 1982; 14(4): 356-60.
72. Foeldvari I, Nielsen S, Kummerle-Deschner J, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 2007; 34: 1146-50.
73. Hale S, Lightman S. Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine 2006; 33: 231-7.
74. Joseph A, Raj D, Dua HS, et al. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003; 110: 1449-53.
75. Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 2005; 89: 533-6.
76. Rajaraman RT, Kimura Y, Li S, et al. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 2006; 113: 308-14.
77. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001; 358: 295-6.
78. Fries W, Giofre MR, Catanoso M, Lo Gullo R. Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab. Am J Gastroenterol 2002; 97: 499-500.
79. Murphy CC, Ayliffe WH, Booth A, et al. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004; 111: 352-6.
80. Saurenmann RK, Levin AV, Rose JB, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology 2006; 45: 982-9.
81. Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006; 113: 860-864 e862.
82. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007; 91(3): 319-24.
83. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005; 52: 2447-51.
84. Mintz R, Feller ER, Bahr RL, Shah SA. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 135-9.
85. Yarur AJ, Czul F, Levy C. Hepatobiliary Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis 2014; 20(9): 1655-67.
86. Olsson R, Danielsson A, Jarnerot G, et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991; 100: 1319-23.
87. Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991; 11: 31-9.
88. Broome U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Seminars in liver disease 2006; 26: 31-41.
89. Tischendorf JJ, Hecker H, Kruger M, et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study. Am J Gastroenterol 2007; 102: 107-14.
90. Joo M, Abreu-e-Lima P, Farraye F, et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am J Surg Pathol 2009; 33: 854-62.
91. Soetikno RM, Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002; 56: 48-54.
92. Loftus EV, Jr., Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005; 54: 91-6.
93. Talwalkar JA, Lindor KD. Primary sclerosing cholangitis. Inflamm Bowel Dis 2005; 11: 62-72.
94. Siemanowski B, Regueiro M. Efficacy of infliximab for extraintestinal manifestations of inflammatory bowel disease. Curr Treat Options Gastroenterol 2007; 10: 178-84.
95. Hommes DW, Erkelens W, Ponsioen C, et al. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. J Clin Gastroenterol 2008; 42: 522-6.
96. Duca I, Ramirez de la Piscina P, Estrada S, et al. Steroid-refractory ulcerative colitis and associated primary sclerosing cholangitis treated with infliximab. World J Gastroenterol 2013; 19: 590-3.